A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Relmada Therapeutics Inc’s current trading price is -90.72% away from its 52-week high, while its distance from the 52-week low is -64.36%. The stock’s price range for this time frame has been between $1.88 and $7.22. The trading volume of the company’s shares in the Healthcare reached around 10.89 million for the day, which was evidently higher than the average daily volume of 0.19 million over the last three months.
In terms of market performance, Relmada Therapeutics Inc had a somewhat inconsistent run in. The highest value for the stock in the past year was $7.22 on 03/04/24, while the lowest value was $1.88 on 12/04/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
Relmada Therapeutics Inc (RLMD) has experienced a quarterly decline of -72.31% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 20.22M and boasts a workforce of 20 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.20, with a change in price of -3.17. Similarly, Relmada Therapeutics Inc recorded 265,980 in trading volume during the last 100 days, posting a change of -82.59%.
How RLMD’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for RLMD stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
RLMD Stock Stochastic Average
The raw stochastic average for Relmada Therapeutics Inc over the last 50 days is presently at 1.44%. This reflects a drop from the raw stochastic average of the previous 20 days, which was noted at 1.68%. Further, the company’s Stochastic %K and %D values for the last 20 days were 26.36% and 35.23%, respectively.
RLMD Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. The metric has seen a significant loss of -83.82% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -77.36%. Over the past 30 days, the price of RLMD has leaped by -80.41%. And in the last five days, it has fallen by -75.37%.
